Celcuity Inc. (CELC) has a MoatMap StockRank of 26/100 based on Quality (25/100), Value (34/100), and Momentum (54/100) factor scores. The current signal is SELL. Celcuity is a clinical-stage biotechnology company with no commercial revenues. This violates our fundamental rule of owning high-ROIC, established compounders with proven owner earnings.
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for oncology, utilizing its proprietary CELsignia companion diagnostic platform. The platform analyzes live tumor cells from patients to identify active signaling pathways, enabling more precise patient selection for its lead drug candidate, gedatolisib. Celcuity's competitive moat is built on this integrated approach of combining functional cellular diagnostics with targeted therapeutic development.
| Price | $92.59 |
| Market Cap | $6.4B |
| P/E (Forward) | 124.96 |
| Price/Book | 83.53 |
| Return on Equity | -275.2% |
| Return on Invested Capital | -37.9% |
| Debt/Equity | 604.28 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-111M |
Celcuity Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).